Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Saxenda safety under the microscope: new study monitors side effects in Real-World patients

NCT ID NCT02773355

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how well doctors can detect serious and non-serious side effects of the weight-loss drug Saxenda (liraglutide) in 27 Mexican patients with obesity. The main goal was to track cases of pancreatitis and other possible drug reactions. Patients took Saxenda as part of their normal care, and researchers recorded any adverse events that came up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liraglutide (Saxenda)
What this could lead to
If successful, this could improve how doctors monitor and catch side effects of Saxenda in real-world settings, leading to safer use for obesity.
What could go wrong
This is a small, observational study with only 27 patients, so results may not apply broadly. It does not test if Saxenda works for weight loss, only safety monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

27 people

The number who actually took part.

Started

May 2016

Finished

Feb 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The medical condition investigated in this study is obesity and overweight with one or more weight related comorbidities. The study will aim at observing all patients exposed to Saxenda® during treatment by the 20 participating physicians in Mexico.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * The decision to initiate the treatment with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study * Obese patients (BMI equal to or above 30 kg/m\^2) or overweight patients (BMI Equal to or above 27 kg/m\^2) with at least one weight related comorbidity according to Saxenda® label text in Mexico * Age equal or above 18 years at the time of signing informed consent Exclusion Criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Hypersensitivity to Saxenda® or to any of its excipients * Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) * Diagnosis of type 1 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Centro de Investigacion Clinica Endocrinologica de Jalisco

    Guadalajara, Jalisco, 44670, Mexico

  • Especialidades Médicas del Bosque

    Guadalajara, Jalisco, 44520, Mexico

  • Hospital Angeles de Puebla

    Puebla City, 72190, Mexico

  • Hospital Angeles de las Lomas

    México, State of Mexico, 52763, Mexico

  • Hospital Bite Medica

    Mexico City, México, D.F., 01330, Mexico

  • Hospital CIMA Hermosillo

    Hermosillo, Sonora, 83270, Mexico

  • Hospital HMG Coyoacan

    Mexico City, México, D.F., 04380, Mexico

  • Hospital San Angel Inn

    Mexico City, México, D.F., 03339, Mexico

  • Hospital San Angel Inn_Mexico City

    Mexico City, México, D.F., 06700, Mexico

  • Investigación Clínica Especializada, S.C.

    Guadalajara, Jalisco, 44600, Mexico

  • Medica Sur

    Mexico City, 14050, Mexico

  • Torre Médica Dalinde

    Mexico City, México, D.F., 06760, Mexico

  • Unidad Médica Dentistas

    Guadalajara, Jalisco, 44679, Mexico

  • Zrii de México Ejecutivo Independiente

    Monterrey, Nuevo León, 66220, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.